Advancing Metabolic Research in NASH, Obesity, and Cachexia Through Pfizer’s ASPIRE Program
Did you know that certain metabolic diseases are connected to one another by underlying biological factors? Non-alcoholic steatohepatitis (NASH), obesity, and cachexia are directly linked with heart health, and together they constitute a global public health concern that risks reaching epidemic proportions.
Pfizer is working to discover new medicines to help solve the significant patient needs associated with these conditions, but we recognize that no one company will be able to successfully accomplish this task on their own.
“The global healthcare community must continue to work collectively to better understand these conditions, says William Sessa, Ph.D., Senior Vice President and Chief Scientific Officer, Internal Medicine at Pfizer. “Together, we need to better understand how they are intrinsically connected as we work to discover new medicines that will improve the health and daily experience of patients and their families.”
One way that Pfizer embraces this collective approach is by supporting independent research through our Advancing Science and Patient care through Innovative Research and Education (ASPIRE) Competitive Grants programs in NASH, obesity, and cachexia. This program fuels the advancement of medical knowledge of these hard-to-treat conditions that impact hundreds of millions of people across the globe.
As we prepare to open the ASPIRE Competitive Research Grants application process for 2023, with grants to be awarded in 2024, we especially encourage those who are passionate about advancing knowledge of NASH to apply. We greatly value the external innovation of independent researchers, which contributes to our shared goal of unearthing new scientific discoveries that will hopefully translate to innovative medicines for patients around the world.
Previous grant recipients and their institutions, highlighted below, are leading innovative projects to uncover insights on the origin and progression of NASH, obesity and cachexia and we’re thrilled to continue to support independent research.
NASH
- Matthew Hoare, University of Cambridge
- Laura Calabresi, Università degli Studi di Milano
- Bo Wang, University of Illinois at Urbana-Champaign
- Mar Coll, Universitat de Barcelona
- Andrea Branch, Icahn School of Medicine at Mount Sinai
- Ekaterina Smirnova, Virginia Commonwealth University
Obesity
- Elena Bochukova, Queen Mary University of London
- Lisa Cannon-Albright, University of Utah
- Ana Domingos, University of Oxford
- Paul Sabatini, The Research Institute of the McGill University Health Centre
- Charles LeDuc, Columbia University
Cachexia
- Hannah Wardill, The University of Adelaide
- Paul Sabatini, The Research Institute of the McGill University Health Centre
- Jackson Orem, Uganda Cancer Institute
05.01.2024 Albert Bourla Cancer Covid-19 Diversity & Inclusion Leadership Vaccines April Social Media Round-Up—Black Maternal Health, World Immunization, and Long Covid 04.30.2024 Cancer Covid-19 Leadership Technology Pfizer Goes Live in SXSW’s Podcast Lounge 04.09.2024 Albert Bourla Cancer Diversity & Inclusion Leadership March Social Media Round-Up—Annual Review, International Women’s Day, and a School of Science Celebration 04.05.2024 Breast Cancer Cancer Research Working to “Outdo” Cancer: A Multi-Modality Approach to Accelerating the Next Generation of Cancer Breakthroughs 03.27.2024 Health Equity Partnerships Rare Diseases Pfizer Teams With Black British Choir to Bring Awareness to Sickle Cell, Rare Diseases